Heart Test Laboratories (Heart Test Laboratories) GF Value : $0.00 (As of Jun. 10, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Heart Test Laboratories GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-06-10), Heart Test Laboratories's share price is $5.83. Heart Test Laboratories's GF Value is $0.00. Therefore, Heart Test Laboratories's Price-to-GF-Value for today is .

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Heart Test Laboratories is Not Valued.

Heart Test Laboratories (NAS:HSCS) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Heart Test Laboratories's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	5.83	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heart Test Laboratories GF Value Related Terms

Thank you for viewing the detailed overview of Heart Test Laboratories's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Heart Test Laboratories (Heart Test Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heart Test Laboratories Inc (NAS:HSCS) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

550 Reserve Street, Suite 360, Southlake, TX, USA, 76092

Website

https://www.heartsciences.com

Heart Test Laboratories Inc is a medical technology company focused on applying innovative AI-based technology to an ECG to expand and improve an ECG's clinical usefulness. The objective of the company is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings.

Executives

David R. Wells	director	2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Bruce Bent	director	750 BONHAM PARKWAY, LANTANA TX 76226
Mark T Hilz	director, officer: See Remarks	3301 DAKOTA DRIVE, NORTHLAKE TX 76226
Patrick Kanouff	director	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Brian Szymczak	director	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Danielle Watson	officer: See Remarks	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Andrew Simpson	director, officer: See Remarks	550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092